BioLife Solutions, Inc.

NasdaqCM:BLFS Rapporto sulle azioni

Cap. di mercato: US$1.1b

BioLife Solutions Performance dei guadagni passati

Il passato criteri di controllo 0/6

Gli utili di BioLife Solutions sono diminuiti a un tasso medio annuo di -45%, mentre il settore Life Sciences ha visto gli utili crescere a un tasso medio annuo di 11.7%. I ricavi sono cresciuti crescere a un tasso medio annuo di 28.6%.

Informazioni chiave

-45.0%

Tasso di crescita degli utili

-40.2%

Tasso di crescita dell'EPS

Life Sciences Crescita del settore21.5%
Tasso di crescita dei ricavi28.6%
Rendimento del capitale proprio-15.2%
Margine netto-33.6%
Ultimo aggiornamento sui guadagni30 Sep 2024

Aggiornamenti sulle prestazioni recenti

Recent updates

Analysts Have Lowered Expectations For BioLife Solutions, Inc. (NASDAQ:BLFS) After Its Latest Results

Nov 15
Analysts Have Lowered Expectations For BioLife Solutions, Inc. (NASDAQ:BLFS) After Its Latest Results

Is BioLife Solutions (NASDAQ:BLFS) Using Debt Sensibly?

Oct 25
Is BioLife Solutions (NASDAQ:BLFS) Using Debt Sensibly?

Is There An Opportunity With BioLife Solutions, Inc.'s (NASDAQ:BLFS) 20% Undervaluation?

Sep 14
Is There An Opportunity With BioLife Solutions, Inc.'s (NASDAQ:BLFS) 20% Undervaluation?

Why BioLife Solutions, Inc. (NASDAQ:BLFS) Could Be Worth Watching

Aug 30
Why BioLife Solutions, Inc. (NASDAQ:BLFS) Could Be Worth Watching

Investors Appear Satisfied With BioLife Solutions, Inc.'s (NASDAQ:BLFS) Prospects As Shares Rocket 28%

Aug 14
Investors Appear Satisfied With BioLife Solutions, Inc.'s (NASDAQ:BLFS) Prospects As Shares Rocket 28%

BioLife Solutions (NASDAQ:BLFS) Has Debt But No Earnings; Should You Worry?

Jun 20
BioLife Solutions (NASDAQ:BLFS) Has Debt But No Earnings; Should You Worry?

A Look At The Fair Value Of BioLife Solutions, Inc. (NASDAQ:BLFS)

Jun 05
A Look At The Fair Value Of BioLife Solutions, Inc. (NASDAQ:BLFS)

Revenues Not Telling The Story For BioLife Solutions, Inc. (NASDAQ:BLFS) After Shares Rise 25%

May 14
Revenues Not Telling The Story For BioLife Solutions, Inc. (NASDAQ:BLFS) After Shares Rise 25%

Broker Revenue Forecasts For BioLife Solutions, Inc. (NASDAQ:BLFS) Are Surging Higher

May 13
Broker Revenue Forecasts For BioLife Solutions, Inc. (NASDAQ:BLFS) Are Surging Higher

Should You Investigate BioLife Solutions, Inc. (NASDAQ:BLFS) At US$19.54?

May 11
Should You Investigate BioLife Solutions, Inc. (NASDAQ:BLFS) At US$19.54?

Does BioLife Solutions (NASDAQ:BLFS) Have A Healthy Balance Sheet?

Mar 12
Does BioLife Solutions (NASDAQ:BLFS) Have A Healthy Balance Sheet?

BioLife Solutions, Inc.'s (NASDAQ:BLFS) Intrinsic Value Is Potentially 64% Above Its Share Price

Feb 19
BioLife Solutions, Inc.'s (NASDAQ:BLFS) Intrinsic Value Is Potentially 64% Above Its Share Price

BioLife Solutions, Inc.'s (NASDAQ:BLFS) Share Price Matching Investor Opinion

Dec 19
BioLife Solutions, Inc.'s (NASDAQ:BLFS) Share Price Matching Investor Opinion

Downgrade: Here's How Analysts See BioLife Solutions, Inc. (NASDAQ:BLFS) Performing In The Near Term

Aug 17
Downgrade: Here's How Analysts See BioLife Solutions, Inc. (NASDAQ:BLFS) Performing In The Near Term

Is BioLife Solutions (NASDAQ:BLFS) Weighed On By Its Debt Load?

Aug 11
Is BioLife Solutions (NASDAQ:BLFS) Weighed On By Its Debt Load?

Health Check: How Prudently Does BioLife Solutions (NASDAQ:BLFS) Use Debt?

May 06
Health Check: How Prudently Does BioLife Solutions (NASDAQ:BLFS) Use Debt?

Should You Think About Buying BioLife Solutions, Inc. (NASDAQ:BLFS) Now?

Feb 22
Should You Think About Buying BioLife Solutions, Inc. (NASDAQ:BLFS) Now?

Health Check: How Prudently Does BioLife Solutions (NASDAQ:BLFS) Use Debt?

Jan 10
Health Check: How Prudently Does BioLife Solutions (NASDAQ:BLFS) Use Debt?

Is There An Opportunity With BioLife Solutions, Inc.'s (NASDAQ:BLFS) 20% Undervaluation?

Dec 10
Is There An Opportunity With BioLife Solutions, Inc.'s (NASDAQ:BLFS) 20% Undervaluation?

BioLife: What The Future Holds

Oct 19

Ripartizione dei ricavi e delle spese

Come BioLife Solutions guadagna e spende denaro. In base agli ultimi utili dichiarati, su base LTM.


Storia dei guadagni e delle entrate

NasdaqCM:BLFS Ricavi, spese e utili (USD Millions )
DataRicaviGuadagniSpese G+ASpese di R&S
30 Sep 24147-497415
30 Jun 24140-647517
31 Mar 24141-627818
31 Dec 23143-668019
30 Sep 23126-796915
30 Jun 23143-747015
31 Mar 23155-1417014
31 Dec 22162-1406915
30 Sep 22155-1066714
30 Jun 22148-966414
31 Mar 22139-155714
31 Dec 21119-94812
30 Sep 219753810
30 Jun 21744299
31 Mar 2153-20237
31 Dec 20482227
30 Sep 20427186
30 Jun 203716175
31 Mar 203439154
31 Dec 1927-2143
30 Sep 1925-32122
30 Jun 1923-39112
31 Mar 1922-44101
31 Dec 1820-2591
30 Sep 1817181
30 Jun 1815071
31 Mar 1812-271
31 Dec 1711-371
30 Sep 1710-561
30 Jun 179-672
31 Mar 179-772
31 Dec 168-782
30 Sep 168-582
30 Jun 167-582
31 Mar 167-482
31 Dec 156-471
30 Sep 156-471
30 Jun 156-461
31 Mar 156-461
31 Dec 146-351
30 Sep 147-351
30 Jun 148-241
31 Mar 149-241
31 Dec 139-140

Guadagni di qualità: BLFS al momento non è redditizia.

Margine di profitto in crescita: BLFS al momento non è redditizia.


Flusso di cassa libero e analisi degli utili


Analisi della crescita degli utili nel passato

Andamento degli utili: BLFS non è redditizia e le perdite sono aumentate negli ultimi 5 anni a un tasso pari a 45% all'anno.

Accelerare la crescita: Impossibile confrontare la crescita degli utili di BLFS nell'ultimo anno con la sua media quinquennale poiché al momento non è redditizia

Guadagni vs Settore: BLFS non è redditizia, il che rende difficile confrontare la crescita dei suoi utili dell'anno passato con il settore Life Sciences ( -4.7% ).


Rendimento del capitale proprio

ROE elevato: BLFS ha un Return on Equity negativo ( -15.19% ), in quanto al momento non è redditizio.


Rendimento delle attività


Rendimento del capitale investito


Scoprire le aziende con forti performance passate